Cargando…
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and differentiation. The most clinically important point is that mutation of the FLT3 gene is the most frequent genetic alteration and a poor prognostic...
Autores principales: | Kiyoi, Hitoshi, Kawashima, Naomi, Ishikawa, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004512/ https://www.ncbi.nlm.nih.gov/pubmed/31821677 http://dx.doi.org/10.1111/cas.14274 |
Ejemplares similares
-
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019) -
Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
por: Adachi, Yoshiya, et al.
Publicado: (2017) -
FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018) -
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)